Loncastuximab
Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine[2].
Product Specifications
CAS Number
1875032-68-0
Product Name Alternative
RB4v1.2
UNSPSC
12352203
Target
ADC Antibody; CD19
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/loncastuximab.html
Purity
99.0
Solubility
10 mM in DMSO
Smiles
[Loncastuximab]
Molecular Weight
(144.46 kDa)
References & Citations
[1]Zinzani PL, et al. Anti-CD19 monoclonal antibodies for the treatment of relapsed or refractory B-cell malignancies: a narrative review with focus on diffuse large B-cell lymphoma. J Cancer Res Clin Oncol. 2022 Jan;148 (1) :177-190. |[2]Hess B, et al. Efficacy and Safety Exposure-Response Analysis of Loncastuximab Tesirine in Patients with B cell non-Hodgkin Lymphoma. AAPS J. 2021 Dec 10;24 (1) :11.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC402616-500 1x 500 µL
Cadherin 17 / LI Cadherin (Liver-Intestine Marker) (CDH17/2616), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
